OncoCyte Corp
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test tha… Read more
Market Cap & Net Worth: OncoCyte Corp (OCX)
OncoCyte Corp (NASDAQ:OCX) has a market capitalization of $90.37 Million ($90.37 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24548 globally and #8468 in its home market, demonstrating a 14.70% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OncoCyte Corp's stock price $3.16 by its total outstanding shares 28599300 (28.60 Million).
OncoCyte Corp Market Cap History: 2015 to 2025
OncoCyte Corp's market capitalization history from 2015 to 2025. Data shows change from $3.57 Billion to $90.37 Million (-33.99% CAGR).
Index Memberships
OncoCyte Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #661 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2149 of 3165 |
Weight: OncoCyte Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
OncoCyte Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OncoCyte Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
36.19x
OncoCyte Corp's market cap is 36.19 times its annual revenue
0.69x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $1.29 Billion | $16.00K | -$22.33 Million | 80435.53x | N/A |
| 2020 | $1.37 Billion | $1.22 Million | -$29.93 Million | 1124.22x | N/A |
| 2021 | $1.24 Billion | $7.73 Million | -$64.10 Million | 160.63x | N/A |
| 2022 | $183.55 Million | $958.00K | -$73.44 Million | 191.60x | N/A |
| 2023 | $71.50 Million | $1.50 Million | -$27.78 Million | 47.57x | N/A |
| 2024 | $68.07 Million | $1.88 Million | -$60.66 Million | 36.19x | N/A |
Competitor Companies of OCX by Market Capitalization
Companies near OncoCyte Corp in the global market cap rankings as of March 18, 2026.
Key companies related to OncoCyte Corp by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
OncoCyte Corp Historical Marketcap From 2015 to 2025
Between 2015 and today, OncoCyte Corp's market cap moved from $3.57 Billion to $ 90.37 Million, with a yearly change of -33.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $90.37 Million | +32.77% |
| 2024 | $68.07 Million | -4.80% |
| 2023 | $71.50 Million | -61.05% |
| 2022 | $183.55 Million | -85.21% |
| 2021 | $1.24 Billion | -9.21% |
| 2020 | $1.37 Billion | +6.22% |
| 2019 | $1.29 Billion | +63.04% |
| 2018 | $789.34 Million | -70.32% |
| 2017 | $2.66 Billion | -34.04% |
| 2016 | $4.03 Billion | +12.80% |
| 2015 | $3.57 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of OncoCyte Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $90.37 Million USD |
| MoneyControl | $90.37 Million USD |
| MarketWatch | $90.37 Million USD |
| marketcap.company | $90.37 Million USD |
| Reuters | $90.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.